#centralnervoussystem

MapLight Therapeutics News

SandboxAQ and MapLight Therapeutics (Nasdaq: MPLT) established a collaborative cooperation to find and develop first-in-class CNS diseases medicines, transforming neuropsychiatric medicine. With circuit-specific neuroscience, high-fidelity molecular simulation, and cutting-edge AI, the cooperation takes a bold move towards solving brain health's biggest concerns.

The arrangement involves an upfront payment to SandboxAQ and possible $200 million milestone payments in addition to future royalties.

An Innovative CNS Treatment

For decades, drug development for CNS diseases like schizophrenia, autism, and Parkinson's has failed and yielded ambiguous outcomes. Traditional methods sometimes use broad-spectrum methods that harm numerous brain regions.

MapLight Therapeutics was founded to combat this “circuit-blind” approach. MapLight aims to identify disease-causing neural circuits to design treatments that don't affect brain function. About one-third of FDA-approved drugs target a unique G protein-coupled receptor (GPCR), a cell surface protein. This new alliance targets it.

SandboxAQ's AQBioSim platform drives this partnership. SandboxAQ, a spinoff of Alphabet Inc., uses “Large Quantitative Models” (LQMs) to go beyond standard AI using high-performance computers and quantum physics.

SandboxAQ's simulation-first approach lets researchers predict molecular interactions from scratch, unlike typical AI models that use existing data. In the MapLight cooperation, SandboxAQ will employ these models:

Examine Receptor Structure: Map the target GPCR's complex three-dimensional shape and function with atomic-level accuracy.

Predict Interaction: Virtually explore millions of chemicals to detect receptor binding.

Improve Drug Properties: Ensure chemical structures are safe, effective, and blood-brain barrier-crossing.

Andrea Bortolato, SandboxAQ's vice president of drug development, said, “Our platform allows a systematic, data-driven exploration of chemical space that has eluded traditional approaches.” By speeding up the DMTA cycle, the companies hope to reach clinical trials years sooner than traditional pharmaceutical timelines.

Contract Terms

The strategy structure divides preclinical research across both companies. MapLight provides CNS biology and clinical validation expertise, while SandboxAQ models and selects the best therapeutic candidates.

After finding a candidate, MapLight Therapeutics will develop and commercialise them alone. MapLight can use its clinical infrastructure to bring these new medications through the FDA's rigorous approval process.

Innovative Leaders

This partnership unites two “Quantum and AI” titans. According to MapLight Chief Scientific Officer James Lillie, the target GPCR has been validated using MapLight's proprietary platform, making it possible for SandboxAQ's AI to accelerate.

The recent public listing of MapLight (Nasdaq: MPLT) and SandboxAQ's development into life sciences highlight a larger trend: biology and technology converging. This partnership reinforces SandboxAQ's LQM leadership and expands on their past successful relationships with world health leaders.

Patients Should Care

About one billion people worldwide have CNS diseases. James Lillie's “unmet need” is the millions of people who have no treatment alternatives or suffer from debilitating drug side effects.

Its uniqueness gives this cooperation potential. If SandboxAQ's simulations uncover a molecule that binds to a sick circuit's GPCR, the treatment may be safer and more effective than current options.

Looking Ahead

This partnership shows how quantum-inspired technology are benefiting society as the “International Year of Quantum” ends. The $200 million milestone sum shows the deal's financial potential, but the scientific shift from “hit-or-miss” drug development to “predictive” molecular engineering might transform biotech in ten years.

The brain stem is a vital structure of the central nervous system, located at the base of the brain and connecting it to the spinal cord. It plays an essential role in many bodily functions, including the coordination of movement.

Role of the brain stem in motor function

The brain stem contains motor nuclei, groups of neurons involved in the control of movement. These motor nuclei receive information from the brain, cerebellum and spinal cord, and transmit it to the muscles via the cranial nerves and descending spinal cord pathways.

More specifically, the brainstem is involved in:

- Control of voluntary movements ‍♀️: The motor nuclei of the brainstem, in collaboration with the motor cortex, cerebellum and basal ganglia, are involved in the planning, initiation and execution of voluntary movements.

- Control of reflex movements ️: The brainstem contains reflex centers that control automatic and involuntary movements, such as coughing, yawning, swallowing and the blink reflex.

- Maintaining balance and posture : The brainstem receives information from the balance organs (inner ear) and the body's sensory receptors, and uses it to adjust posture and maintain balance.

- Controlling eye, head and facial movements ️: The motor nuclei of the brainstem control the muscles that move the eyes, head and face.

Structure of the brain stem

The brainstem is made up of three main parts:

- The mesencephalon: This is the upper part of the brainstem, containing motor nuclei involved in controlling eye movements and visual and auditory reflexes.

- Bridge: This is the middle part of the brain stem, containing motor nuclei involved in controlling head and facial movements, as well as nerve fibers connecting the brain to the cerebellum.

- Medulla oblongata: This is the lower part of the brain stem, containing motor nuclei involved in controlling vital functions such as breathing, heart rate and blood pressure.

Brain stem injuries

Brain stem lesions can lead to a variety of motor disorders, such as :

- Hemiplegia

- Ataxia

- tremors

- Balance disorders

- Speech disorders

- Swallowing disorders

- Breathing disorders

Conclusion

The brainstem is an essential structure of the central nervous system, playing a crucial role in the coordination of movement, as well as in many other vital functions.